Oruka Therapeutics (ORKA) Price & Analysis

Compare

720 Followers

ORKA Stock Chart & Stats

$28.28

-$0.35(-1.84%)

At close: Jan 08 4:00 PM EST

$28.28

-$0.35(-1.84%)

Day’s Range― - ―

52-Week Range$5.49 - $31.13

Previous CloseN/A

Volume71.58K

Average Volume (3M)530.53K

Market Cap

$1.33B

Enterprise Value$148.75M

Total Cash (Recent Filing)$328.41M

Total Debt (Recent Filing)$2.33M

Price to Earnings (P/E)―

Beta0.78

Next Earnings

Nov 12, 2025

EPS Estimate

-0.58

Last Dividend Ex-Date

Aug 29, 2024

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding48,384,150

10 Day Avg. Volume602,310

30 Day Avg. Volume530,527

Financial Highlights & Ratios

PEG Ratio-0.31

Price to Book (P/B)0.85

Price to Sales (P/S)0.00

P/FCF Ratio-5.61

Enterprise Value/Market Cap0.11

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.80K

Enterprise Value/Ebitda-1.50

Forecast

1Y Price Target

$47.29

Price Target Upside67.22% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial StabilityOruka has completed a private investment in public equity (PIPE) financing resulting in gross proceeds of approximately $180M, providing financial stability and operational runway well into 2028.

Market PositionORKA is the only other clinical-stage IL-17A/F targeted therapy that we are aware of besides MoonLake Immunotherapeutics.

Product PotentialSingle doses of ORKA-001 demonstrated complete and sustained inhibition of STAT3 signaling, a downstream marker of IL-23 activity, in an ex vivo assay through 24 weeks, suggesting potential effectiveness.

Bears Say

Clinical TrialsOnly one of two Ph3 trials in moderate-to-severe hidradenitis suppurativa met its primary endpoint.

Oruka Therapeutics News

Oruka Therapeutics initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $60 price target citing a positive...

12d ago

ORKA

Oruka Therapeutics price target lowered to $40 from $45 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Oruka Therapeutics (ORKA) to $40 from $45...

12d ago

ORKA

Oruka Therapeutics initiated with an Overweight at Barclays

Barclays initiated coverage of Oruka Therapeutics (ORKA) with an Overweight rating and $48 price target The firm launched...

26d ago

ORKA

Oruka Therapeutics’ Promising Psoriasis Study: What Investors Need to Know

Oruka Therapeutics, Inc. (($ORKA)) announced an update on their ongoing clinical study. Oruka Therapeutics, Inc. is conducting a...

11d ago

ORKA

Oruka Therapeutics files to sell 39.43M shares of common stock for holders

17:21 EDT Oruka Therapeutics (ORKA) files to sell 39.43M shares of common stock for holders Published first on...

1M ago

ORKA

Promising Future for Oruka Therapeutics: Buy Rating Backed by ORKA-002’s Market Potential and Strategic Expansion

BTIG analyst Julian Harrison has maintained their bullish stance on ORKA stock, giving a Buy rating on September...

1M ago

ORKA

Oruka Therapeutics’ ORKA-002: Promising Alternative with Competitive Edge in Hidradenitis Suppurativa and Psoriasis

Leerink Partners analyst David Risinger has reiterated their bullish stance on ORKA stock, giving a Buy rating on...

1M ago

ORKA

Leerink sees greater opportunity for Oruka’s ORKA-002 after MoonLake news

Leerink expects Oruka Therapeutics (ORKA) shares to trade higher following MoonLake Immunotherapeutics’ (MLTX) disclosure of mixed Phase 3...

1M ago

MLTX

ORKA

Oruka Therapeutics jumps 28% after MoonLake data miss

Shares of Oruka Therapeutics (ORKA) are up 28%, or $4.31, to $19.51 in midday trading after MoonLake Immunotherapeutics...

1M ago

MLTX

ORKA

Oruka Therapeutics Secures $180M in Private Placement

Oruka Therapeutics ( ($ORKA) ) just unveiled an announcement. On September 17, 2025, Oruka Therapeutics announced a Securities...

2M ago

ORKA

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Earnings reports, Federal Reserve decisions, and more have the stock market on the move today. ...

2M ago

AMD

Oruka Therapeutics data hits ‘bull case’ scenario, says Clear Street

Clear Street says Oruka Therapeutics (ORKA)’ data for ORKA-001 hit the “bull case.” Initial data from the Phase...

2M ago

ORKA

Oruka Therapeutics sells 10.9M shares at $15 in private placement

Oruka Therapeutics (ORKA) announced that it has entered into a securities purchase agreement for a private investment in...

2M ago

ORKA

Oruka Therapeutics announces interim data from ORKA-001 trial at EADV

Oruka Therapeutics (ORKA) announced interim data from its Phase 1 trial of ORKA-001, the company’s long-acting IL-23p19 antibody,...

2M ago

ORKA

ORKA FAQ

What was Oruka Therapeutics’s price range in the past 12 months?

Oruka Therapeutics lowest stock price was $5.49 and its highest was $31.13 in the past 12 months.

What is Oruka Therapeutics’s market cap?

Oruka Therapeutics’s market cap is $1.33B.

When is Oruka Therapeutics’s upcoming earnings report date?

Oruka Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 4 days.

How were Oruka Therapeutics’s earnings last quarter?

Oruka Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.49 by $0.03.

Is Oruka Therapeutics overvalued?

According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oruka Therapeutics pay dividends?

Oruka Therapeutics pays a Notavailable dividend of $19.356 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics dividends here

What is Oruka Therapeutics’s EPS estimate?

Oruka Therapeutics’s EPS estimate is -0.58.

How many shares outstanding does Oruka Therapeutics have?

Oruka Therapeutics has 48,384,150 shares outstanding.

What happened to Oruka Therapeutics’s price movement after its last earnings report?

Oruka Therapeutics reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.49. Following the earnings report the stock price went up 6.897%.

Which hedge fund is a major shareholder of Oruka Therapeutics?

Currently, no hedge funds are holding shares in ORKA

Oruka Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-53.15%

Trailing 12-Months

Asset Growth

956.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oruka Therapeutics

Oruka Therapeutics (ORKA) is a biotechnology company focused on developing innovative therapies for rare and complex diseases. Operating within the pharmaceutical and healthcare sectors, Oruka Therapeutics specializes in cutting-edge drug discovery and development, utilizing advanced technologies to address unmet medical needs. The company's core offerings include a pipeline of proprietary therapeutics aimed at improving patient outcomes and enhancing quality of life.

Oruka Therapeutics (ORKA) Earnings & Revenues

Historic Earnings Reports

ORKA Stock 12 Month Forecast

Average Price Target

$47.29

▲(67.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","61":"$61","21.25":"$21.3","34.5":"$34.5","47.75":"$47.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$47.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,21.25,34.5,47.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.62,21.803076923076922,24.986153846153847,28.16923076923077,31.35230769230769,34.535384615384615,37.71846153846154,40.901538461538465,44.08461538461538,47.2676923076923,50.450769230769225,53.63384615384615,56.816923076923075,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.62,20.825384615384618,23.03076923076923,25.236153846153847,27.441538461538464,29.646923076923077,31.852307692307694,34.05769230769231,36.26307692307692,38.46846153846154,40.673846153846156,42.87923076923077,45.08461538461539,{"y":47.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.62,20.264615384615386,21.90923076923077,23.553846153846155,25.19846153846154,26.84307692307692,28.487692307692306,30.13230769230769,31.776923076923076,33.42153846153846,35.066153846153846,36.71076923076923,38.355384615384615,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >